Medication info
DuoStar Tablet 80/10 mg

DuoStar Tablet 80/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Celltrion Pharm, Co., Ltd.
Appearance
Bright blue oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Active

MFDS item code 201906994 · Approved 2019.09.30 · Insurance code 693903150

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to a maximum of 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, an additional blood pressure-lowering effect is observed. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience.

Ingredients

Manufacturer
Celltrion Pharm, Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
View approved original text

This drug is used for patients who need to take both Telmisartan and Rosuvastatin. Telmisartan helps lower essential hypertension and the risk of cardiovascular diseases, especially reducing the risk of myocardial infarction, stroke, and cardiovascular death in high-risk patients aged 55 and older. Rosuvastatin is effective in lowering cholesterol levels when used with a diet in patients with hypercholesterolemia and hyperlipidemia and slows the progression of atherosclerosis. It also reduces the risk of stroke and myocardial infarction in middle-aged patients with risk factors for cardiovascular disease. The combination of these two drugs helps manage blood pressure and lipid levels, thus improving cardiovascular health. Therefore, this medication is used for the prevention and treatment of cardiovascular diseases.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to a maximum of 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, an additional blood pressure-lowering effect is observed. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Do not take this medication if you have allergies to this drug or its components, are pregnant or may become pregnant, or are nursing. Patients with severely impaired liver function or problems with bile secretion, unexplained elevated liver enzyme levels, or muscle diseases should also avoid this medication. Patients with severe renal impairment or those co-administered with specific immunosuppressants, as well as those with diabetes or moderate to severe kidney problems, are advised not to use this medication together. Patients at high risk for muscle disease, for example, those with reduced kidney function, patients with hypothyroidism, those with a family history of muscle disease, and those taking other lipid-lowering drugs should exercise caution when taking this medication. This medication contains lactose; thus, patients with lactose intolerance should not take it. Elderly patients or those with high potassium levels or mild to moderate liver function impairment should use this medication carefully and may need dosage adjustments. Regular liver function tests and muscle enzyme tests should be carried out while using this medication, and if symptoms such as muscle pain, weakness, or cramps occur, patients should consult their doctor immediately. If unexplained muscle pain occurs during this medication, especially if muscle enzyme levels increase to more than five times the normal upper limit, discontinuation of the medication is necessary. Since this medication can affect liver function, patients with a history of liver disease should undergo liver function tests before and during treatment. As this drug has a blood pressure-lowering effect, symptoms of hypotension, dizziness, and fainting may occur, and immediate communication with a healthcare provider is essential if these symptoms are present. Patients using this drug should refrain from alcohol consumption and consult a doctor when combining this drug with others that may affect liver health. Additionally, this drug may interact with certain medications, so patients must inform their healthcare provider of any other medications they are taking. Caution is advised when operating vehicles or dangerous machinery, as drowsiness or dizziness may occur.

Side effects

Headache, position-related dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, ALT elevation, painful urination, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver disorders, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, liver failure, impaired memory, forgetfulness, amnestic syndrome, memory disorders, confusion, myasthenia gravis, ocular myasthenia, constipation, nausea, pancreatitis, pruritus, myopathy, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication over time.

Appearance and packaging

Appearance

Bright blue oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.